Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation

Hypotheses and Specific Aims: Atrial fibrillation is common and increases the risk of thromboembolic events. Current national guidelines recommend long-term treatment with warfarin, an oral anti-coagulant, for patients with atrial fibrillation and multiple thromboembolic risk factors. Adherence to warfarin is important because of its narrow therapeutic window, which requires frequent lab monitoring (i.e., INR) and dose adjustment. The majority of veterans on warfarin are managed in anti-coagulation clinics staffed by pharmacists who routinely contact patients to remind them to get blood draws, to re-enforce medication adherence, and to adjust warfarin dose based on INR values. Sub-therapeutic anti-coagulation increases the risk of thromboembolic events and is most commonly due to poor medication adherence. Dabigatran is a newly approved oral factor X inhibitor medication that is more efficacious than warfarin for lowering the risk of stroke and systemic embolism in patients with atrial fibrillation. Additional advantages of dabigatran include fewer drug-drug interactions and standard dosing, eliminating the need for dose titration or lab monitoring. However, adherence is an important consideration with dabigatran because it is a twice a day medication and requires monthly refills due to its formulation, both of which are strong risk factors for non-adherence. In addition, patients taking dabigatran will not be followed in anti-coagulation clinics because there is no lab value to monitor, and therefore, they will no longer benefit from the adherence support provided by these clinics. Non-adherence to chronic cardiovascular medications is common and non-adherence to dabigatran may potentially limit its effectiveness in routine clinical use. Rivaroxaban is a newly approved, Factor Xa inhibitor, oral medication prescribed to reduce the risk of stroke and systemic embolism among patients with atrial fibrillation. Rivaroxaban is a once daily medication that is recommended to be taken during an evening meal to reduce the potential risk of decreased efficacy of therapy. In a randomized, double-blind study comparing warfarin to Rivaroxaban, Rivaroxaban was found non-inferior to warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and the risk of major and critically relevant non-major bleeding were similar between the two anticoagulants. In addition, patients taking Rivaroxaban will not be followed in anti-coagulation clinics because there is no lab value to monitor, and therefore, they will no longer benefit from the adherence support provided by these clinics. Non-adherence to chronic cardiovascular medications is common and non-adherence to Rivaroxaban may potentially limit its effectiveness in routine clinical use. Apixaban is a FDA approved anticoagulant, Factor Xa inhibitor, oral medication prescribed to reduce the risk of stroke and blood clots among patients with atrial fibrillation. Apixaban is taken twice daily. In a double-blind, double-dummy, randomized, non-inferior and superior controlled trial, apixaban was found to be superior to warfarin in reducing stroke, systemic embolism, and death. In addition, patients taking apixaban will not be followed in anti-coagulation clinics because there is no lab value to monitor, and therefore, they will no longer benefit from the adherence support provided by these clinics. Non-adherence to chronic cardiovascular medications is common and non-adherence to apixaban may potentially limit its effectiveness in routine clinical use. It is anticipated that many patients will be switched to dabigatran following recent publication of criteria for dabigatran use from the VA National Pharmacy Benefits Management Program. This provides an opportune time to conduct the proposed study focusing on adherence to dabigatran, rivaroxaban, and apixaban. We will first perform qualitative interviews with patients (n\~30) and pharmacists (n\~20) to better understand barriers and facilitators to dabigatran adherence. Informed by the qualitative findings and the literature on interventions to improve cardiovascular medication adherence, we will develop and pilot test a multi-faceted intervention to improve adherence among patients recently started on dabigatran, rivaroxaban, and apixaban. The proposal is innovative because it proactively addresses dabigatran adherence. This pilot will provide preliminary data for an eventual implementation study to assess the effectiveness of the intervention to improve adherence to dabigatran and patient outcomes, as well as its cost-effectiveness. Specific aims 1. Conduct in-depth, key informant interviews with a sample of patients (n=30) recently started on dabigatran for atrial fibrillation to determine barriers and facilitators to dabigatran adherence. 2. Conduct in-depth, key informant interviews with a sample of pharmacists (n=20) in anti-coagulation clinics in order to understand their perspectives on barriers and facilitators to patients' maintaining adherence to dabigatran. 3. Informed by the qualitative interviews, develop and pilot test a multi-faceted intervention targeting patients and pharmacists to improve adherence to dabigatran, rivaroxaban, and apixaban. II. Background and Significance: Atrial fibrillation is common, affecting 2.2 million Americans and is likely to increase with the aging of the US population. The most devastating sequelae of atrial fibrillation is stroke. National guidelines recommend warfarin, an oral anticoagulant for patients with atrial fibrillation and multiple risk factors (e.g., hypertension, diabetes, older age, stroke or TIA, heart failure) to reduce the stroke risk. Veterans prescribed warfarin are usually managed closely in anti-coagulation clinics. Pharmacists staff these clinics, coordinating blood draws, titrating warfarin dose to maintain therapeutic INR levels, and re-enforcing adherence to therapy. Prior meta-analysis suggests that patients on warfarin managed in these clinics have better anticoagulation control compared to patients followed in non-specialized clinics. Dabigatran is a newly approved oral direct thrombin inhibitor that was demonstrated to be more efficacious than warfarin for patients with atrial fibrillation. In the RE-LY trial, dabigatran reduced stroke and systemic embolism (Relative risk 0.66; 95% CI, 0.53 to 0.82; P\<0.001) with a similar risk of major bleeding (3.36% vs. 3.11% per year; for warfarin vs. dabigatran p=0.31). There are several potential advantages of dabigatran over warfarin, including: 1) standard dosing without need for dose adjustment; 2) no need for lab monitoring; and 3) fewer drug-drug interactions. For these reasons, dabigatran may be preferred by patients requiring chronic anti-coagulation therapy for atrial fibrillation. Non-adherence to cardiovascular medications is common and limits the effectiveness of medications in routine clinical practice. For most chronic cardiovascular medications, adherence rates begin to decline following the initial prescription, particularly for medications that need to be taken more than once daily, treat asymptomatic conditions and require frequent refills. A prior study found that only \~25% of patient prescribed statins for primary prevention were still adherent at 2 years from the index prescription. The benefits of dabigatran seen in the clinical trial may be significantly lessened if adherence to dabigatran is similar to other chronic cardiovascular medications. This issue of non-adherence is particularly germane to dabigatran because it is a twice a day medication, requires monthly refills due to the formulation of the medication and is used generally as a primary prevention medication for an asymptomatic condition. In the ROCKET AF Study, Rivaroxaban was found to be non-inferior to warfarin for the prevention of stoke and systemic embolism in patients with atrial fibrillation. Rivaroxaban was non-inferior to warfarin and significantly reduced the risk of stroke or systemic embolism by 21% (hazard ratio (HR), 0.79; 95% confidence interval (CI), 0.66 to 0.96; p less than 0.001). The risk of major and clinically relevant non-major bleeding was similar between both anticoagulant drugs. In the ARISTOTLE trial, apixaban had a greater reduction of hemorrhagic stroke compared to the warfarin group (HR 0.51; 95% CI 0.35 to 0.75; p less than 0.001). For the secondary outcome of death from any cause, apixaban was superior to warfarin (HR 0.89; 95% CL 0.8 to 0.998; p=0.047). Pharmacists have helped patients to improve adherence to cardiovascular medications and intermediate outcomes such as BP and LDL control. For anticoagulation therapy, pharmacists have helped patients maintain better INR control via anti-coagulation clinics compared to patients not managed in these clinics. Specific components of anti-coagulation clinics that have been found to be particularly helpful for improving adherence include computerized patient monitoring that identifies delinquent patients (i.e., for lab monitoring) and frequent contacts with the patient. An intervention focusing on adherence involving pharmacists can have the potential to improve dabigatran, rivaroxaban, and apixaban use so that the benefits demonstrated in the clinical trials for dabigatran can be realized in routine clinical practice.